DR info

臨床試験数 : 25 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Acylated and unacylated ghrelin dosages
   University Hospital, Toulouse
      2021   -   NCT04768803   -
Aknemin 50
   Dra. Cristina Avendaño Solá
      2013   -   EUCTR2013-002154-67-ES   Spain;
Betaine
   University of California, San Diego
      2006   -   NCT00348933   United States;
Creatine
   University of California, San Diego
      2006   -   NCT00348933   United States;
GTX-102
   GeneTX Biotherapeutics, LLC
      2020   Phase 1/Phase 2   NCT04259281   Canada;United Kingdom;United States;
Gaboxadol
   Ovid Therapeutics Inc.
      2019   Phase 3   NCT04106557   Australia;Germany;Israel;Netherlands;United States;
Gaboxadol monohydrate 0.5 mg (intended commercial formulation)
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-004478-24-DE   Australia;Germany;Israel;Netherlands;United States;
Gaboxadol monohydrate 0.5 mg capsule
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002907-17-NL   Australia;Germany;Israel;Italy;Netherlands;United States;
Gaboxadol monohydrate 2 mg (intended commercial formulation)
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-004478-24-DE   Australia;Germany;Israel;Netherlands;United States;
Gaboxadol monohydrate 2 mg capsule
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002907-17-NL   Australia;Germany;Israel;Italy;Netherlands;United States;
Gaboxadol monohydrate 5 mg (intended commercial formulation)
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-004478-24-DE   Australia;Germany;Israel;Netherlands;United States;
ION582
   Ionis Pharmaceuticals, Inc.
      2021   Phase 1/Phase 2   NCT05127226   United States;
Levodopa
   Bennett Lavenstein
      2013   -   NCT03235037   -
   Wen-Hann Tan
      2011   Phase 2/Phase 3   NCT01281475   United States;
Levodopa/Carbidopa (4:1)
   Boston Children’s Hospital
      2009   Phase 1   NCT00829439   United States;
MINOCYCLINE HYDROCHLORIDE
   Dra. Cristina Avendaño Solá
      2013   -   EUCTR2013-002154-67-ES   Spain;
Metafolin
   University of California, San Diego
      2006   -   NCT00348933   United States;
Minocycline
   University of South Florida
      2012   -   NCT01531582   United States;
NNZ-2591
   Neuren Pharmaceuticals Limited
      2021   Phase 2   NCT05011851   Australia;
Non disponibile
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 1   EUCTR2019-003787-48-IT   Canada;Italy;Netherlands;Spain;United Kingdom;United States;
Nutritional Formulation Containing Exogenous Ketones
   University of Colorado, Denver
      2018   -   NCT03644693   United States;
OV101
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-004478-24-DE   Australia;Germany;Israel;Netherlands;United States;
      2020   Phase 3   EUCTR2019-002907-17-NL   Australia;Germany;Israel;Italy;Netherlands;United States;
      2019   Phase 2   NCT03882918   Israel;United States;
      2017   Phase 1   NCT03109756   United States;
      -   Phase 3   EUCTR2019-004478-24-NL   Australia;Germany;Israel;Netherlands;United States;
OV101 Regimen 1
   Ovid Therapeutics Inc.
      2016   Phase 2   NCT02996305   Israel;United States;
OV101 regimen 2
   Ovid Therapeutics Inc.
      2016   Phase 2   NCT02996305   Israel;United States;
RO7248824
   Hoffmann-La Roche
      2021   Phase 1   NCT04863794   Netherlands;
      2020   Phase 1   NCT04428281   Canada;Italy;Netherlands;Spain;United Kingdom;United States;
RO7248824/F02-01
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 1   EUCTR2019-003787-48-IT   Canada;Italy;Netherlands;Spain;United Kingdom;United States;
RO7248824/F03-01 (Diluent for RO7248824/F02-01
   F. Hoffmann-La Roche
      2020   Phase 1   EUCTR2019-003787-48-NL   Canada;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 1   EUCTR2019-003787-48-GB   Canada;Italy;Netherlands;Spain;United Kingdom;United States;
Vitamin B12
   University of California, San Diego
      2006   -   NCT00348933   United States;